NSU-MD Faculty Articles
Title
Reversal of tumor-mediated immunosuppression.
ISBN or ISSN
1078-0432
Publication Title
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume
13
Issue
2 Pt 2
Publication Date / Copyright Date
1-15-2007
First Page
727s
Last Page
732s
Publisher
American Association for Cancer Research
DOI Number
10.1158/1078-0432.CCR-06-1924
Abstract
Therapeutic cancer vaccines, one form of active immunotherapy, have long been under investigation; consequently, several vaccine-based strategies have now moved from the bench to the clinical arena. Despite their tremendous promise, current vaccine strategies have shown only limited success in clinical settings, even in renal cell carcinoma (RCC), a prototypical malignancy for the application of immunotherapy. There is ample evidence that, especially in RCC, multiple immunosuppressive mechanisms exist that considerably dampen antitumor responses and weaken the activity of current immunotherapeutic regimens. Therefore, it will be necessary to reverse tumor-mediated immunosuppression before immunotherapies can successfully be applied. Recent insights into the nature and characteristics of the regulatory elements of the immune system have provided new opportunities to enhance vaccine-mediated antitumor immunity and, thereby, increase the chance for improving patient outcome. These new insights represent important considerations for the future design and application of more effective cancer vaccines against RCC and other cancers.
Disciplines
Medicine and Health Sciences
Keywords
Animals, Antigens, Neoplasm, Cancer Vaccines, Humans, Immune Tolerance, Immunosuppression, Immunotherapy, Mice, Models, Biological, Myeloid Cells, Neoplasms, T-Lymphocytes, T-Lymphocytes, Regulatory, Treatment Outcome
NSUWorks Citation
Vieweg, Johannes; Su, Zhen; Dahm, Philipp; and Kusmartsev, Sergei, "Reversal of tumor-mediated immunosuppression." (2007). NSU-MD Faculty Articles. 6.
https://nsuworks.nova.edu/hpd_md_facarticles/6
